Terms: = Kidney tumors AND TET2, Q6N021, MGC125715, KIAA1546, FLJ20032, ENSG00000168769, 54790 AND Treatment
5 results:
1. tet2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
Zhang X; Li S; He J; Jin Y; Zhang R; Dong W; Lin M; Yang Y; Tian T; Zhou Y; Xu Y; Lei QY; Zhang J; Zhang Q; Xu Y; Lv L
Cancer Res; 2022 Jun; 82(11):2097-2109. PubMed ID: 35176127
[TBL] [Abstract] [Full Text] [Related]
2. Ascorbic acid induced tet2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma.
Peng D; He A; He S; Ge G; Wang S; Ci W; Li X; Xia D; Zhou L
Int J Biol Sci; 2022; 18(3):995-1007. PubMed ID: 35173532
[TBL] [Abstract] [Full Text] [Related]
3. tet2 and DNMT3A mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models.
Yang SX; Hollingshead M; Rubinstein L; Nguyen D; Larenjeira ABA; Kinders RJ; Difilippantonio M; Doroshow JH
J Hematol Oncol; 2021 May; 14(1):83. PubMed ID: 34039392
[TBL] [Abstract] [Full Text] [Related]
4. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer.
Elgendy M; Fusco JP; Segura V; Lozano MD; Minucci S; Echeveste JI; Gurpide A; Andueza M; Melero I; Sanmamed MF; Ruiz MR; Calvo A; Pascual JI; Velis JM; Miñana B; Valle RD; Pio R; Agorreta J; Abengozar M; Colecchia M; Brich S; Renne SL; Guruceaga E; Patiño-García A; Perez-Gracia JL
Int J Cancer; 2019 Oct; 145(7):1991-2001. PubMed ID: 30848481
[TBL] [Abstract] [Full Text] [Related]
5. Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma.
Shenoy N; Bhagat TD; Cheville J; Lohse C; Bhattacharyya S; Tischer A; Machha V; Gordon-Mitchell S; Choudhary G; Wong LF; Gross L; Ressigue E; Leibovich B; Boorjian SA; Steidl U; Wu X; Pradhan K; Gartrell B; Agarwal B; Pagliaro L; Suzuki M; Greally JM; Rakheja D; Thompson RH; Susztak K; Witzig T; Zou Y; Verma A
J Clin Invest; 2019 Mar; 129(4):1612-1625. PubMed ID: 30702441
[TBL] [Abstract] [Full Text] [Related]
